Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative bioavailability of cefprozil for oral
suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension
250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting
conditions.